Atezolizumab in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial

By sjmartinez • March 14, 2025

Haddad R, Fayette J, Teixeira M, Prabhash K, Mesia R, Kawecki A, Dechaphunkul A, Dinis J, Guo Y, Masuda M, Hsieh CY, Ghi MG, Vaz de Melo Sette C, Harrington K, Tahara M, Saba NF, Lau A, Jiang T, Yan Y, Ballinger M, Kaul M, Matheny C, Cuchelkar V, Wong DJ. Atezolizumab in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial. JAMA. 2025 Mar 13. doi: 10.1001/jama.2025.1483. Epub ahead of print. PMID: 40079944.

Tags: Hematology/Oncology, Publications

Related Posts

p16INK4a and DNA methylation clocks in women treated with chemotherapy for early breast cancer

Muss HB, Sun C, Ding YC, Ji J, White TA, Nyrop K, LeBrasseur NK, Neuhausen SL, Mitin N, Sedrak MS. p16INK4a and DNA methylation clocks in[...]

Young Women With Pancreatic Cancer: A High-Risk Group for Demoralization

Levi A, Nasr A, Cui Y, Abbas AA, Arouchian TT, Coveler AL, Pierce TL, Anderson BT, Collisson E, Davelaar J, Lo SK, Gaddam S, Gong[...]

Perioperative durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable gastric and gastro-oesophageal junction adenocarcinoma (MATTERHORN): final results of overall survival and event-free survival by pathological response in a global, randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

Janjigian YY, Al-Batran SE, Wainberg ZA, Muro K, Molena D, Van Cutsem E, Hyung WJ, Wyrwicz L, Oh DY, Omori T, Moehler M, Bragagnoli AC,[...]